G1 THERAPEUTICS
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.
G1 THERAPEUTICS
Industry:
Biotechnology Developer Platform Medical Therapeutics
Founded:
2008-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.g1therapeutics.com
Total Employee:
101+
Status:
Active
Contact:
+1 919 213 9835
Email Addresses:
[email protected]
Total Funding:
497.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Amazon
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - G1 Therapeutics
Tavistock Life Sciences
Tavistock Life Sciences investment in Series C - G1 Therapeutics
Franklin Templeton Investments
Franklin Templeton Investments investment in Series C - G1 Therapeutics
Cowen Group
Cowen Group investment in Series C - G1 Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - G1 Therapeutics
Eshelman Ventures
Eshelman Ventures investment in Series C - G1 Therapeutics
Aju IB Investment
Aju IB Investment investment in Series C - G1 Therapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series C - G1 Therapeutics
Mountain Group Capital
Mountain Group Capital investment in Series C - G1 Therapeutics
Lumira Ventures
Lumira Ventures investment in Series C - G1 Therapeutics
Key Employee Changes
Official Site Inspections
http://www.g1therapeutics.com Semrush global rank: 3.87 M Semrush visits lastest month: 3.34 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "G1 Therapeutics" on Search Engine
Our Leadership | G1 Therapeutics, Inc.
John Umstead V. The management team for G1 Therapeutics, is a commercial -stage biopharmaceutical company focused on the development and commercialization of innovative therapies that improve the lives of those affected by cancer.See details»
G1 Therapeutics - Wikipedia
G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.See details»
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in ...
Feb 12, 2024 G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib).See details»
Overview - G1 Therapeutics, Inc.
May 1, 2024 G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib).See details»
Press Releases - G1 Therapeutics, Inc.
Jan 2, 2024 G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024. 2/12/24. G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee. 1/8/24.See details»
Board of Directors | G1 Therapeutics, Inc.
The Board of Directors for G1 Therapeutics, is a commercial -stage biopharmaceutical company focused on the development and commercialization of innovative therapies that improve the lives of those affected by cancer.See details»
G1 Therapeutics - Crunchbase Company Profile & Funding
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the …See details»
- G1 Therapeutics, Inc.
Read more. G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024. Read more. G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee. Read more.See details»
G1 Therapeutics Announces Chief Executive Officer
Sep 30, 2020 RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a company whose mission is to deliver innovative therapies that improve the lives of...See details»
G1 Therapeutics to Release Second Quarter 2023 Financial …
Jul 26, 2023 G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib).See details»
Events & Presentations - G1 Therapeutics, Inc.
5/1/24 at 8:30 AM EDT. G1 Therapeutics 1Q 2024 Financial Results. Click here for Webcast. 4/11/24 at 8:45 AM EDT. 23rd Annual Needham Virtual Healthcare Conference. Click here for Webcast. 3/6/24 at 9:10 PM EST. TD Cowen 44th Annual Health Care Conference: Breast & Lung Cancer Corporate Panel Discussion. Click here for Webcast.See details»
G1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment …
May 1, 2024 G1 Therapeutics Inc is dedicated to developing small-molecule therapies aimed at fulfilling unmet needs in cancer treatment. Its flagship product, COSELA (trilaciclib), is designed to protect...See details»
G1 Therapeutics, Inc. (NASDAQ:GTHX) Just Reported First …
May 4, 2024 Shareholders of G1 Therapeutics, Inc. (NASDAQ:GTHX) will be pleased this week, given that the stock price is up 13% to US$4.49 following its latest first-quarter results. Despite revenues of US ...See details»
G1 Therapeutics - Funding, Financials, Valuation & Investors
Funding. G1 Therapeutics has raised a total of. $697.4M. in funding over 10 rounds. Their latest funding was raised on Nov 17, 2022 from a Post-IPO Equity round. G1 Therapeutics is registered under the ticker NASDAQ:GTHX . Their stock opened with $15.00 in its May 16, 2017 IPO. G1 Therapeutics is funded by 15 investors.See details»
G1 Therapeutics to Participate in the TD Cowen 44th Annual …
Feb 27, 2024 G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib).See details»
gthx-10k_20211231.htm - SEC.gov
Dec 31, 2021 G1 Therapeutics owns all global development and commercial rights across all indications, with the exception of Greater China (Simcere) 1L metastatic Triple negative breast cancer (mTNBC) Registrational trial (enrolling) 2H 2023 Primary: OS. Secondary: PRO, myeloprotection, PFS/ORR 1L Bladder cancer (mUC) Phase 2 trial (enrolling) 4Q …See details»
G1 Therapeutics - Contacts, Employees, Board Members
G1 Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 12. Number of Board Member and Advisor Profiles 3. Contacts 151. About. G1 Therapeutics has 12 current employee profiles, including Chief Medical Officer Rajesh Malik.See details»
Angela Maes - FP&A Manager - G1 Therapeutics, Inc. | LinkedIn
G1 Therapeutics, Inc. Jun 2022 - Present 1 year 11 months. • Implemented monthly budget review process by developing templates for Department Heads to update forecasted budgets, resulting in ...See details»
G1 Therapeutics CEO sells over $178k in company stock
5 days ago G1 Therapeutics, Inc. (NASDAQ: GTHX) President and CEO, Bailey John E. (Jack) Jr., has sold a total of 37,258 shares of company stock, according to a recent SEC filing.The transaction, which took place on May 13, 2024, resulted in a total sale value of approximately $178,421. The shares were sold at prices ranging from $4.62 to $4.98, …See details»